Abstract
The introduction of effective and potent treatments for human immunodeficiency virus (HIV) infection resulted in prolonged survival and better quality of life of HIV-infected patients. However, the longer survival and the anti-HIV medication side effects caused the emergence of new clinical issues, such as the increase in cardiovascular risk, favored by multiple factors, partly related to HIV infection itself, partly to the anti-HIV molecules. HIV infection itself may affect cardiovascular risk through chronic inflammation induced by uncontrolled viral replication, whereas long-term antiretroviral therapy may increase the cardiovascular risk through several mechanisms. Thus, due to the multiple and conflicting causes of cardiovascular disorders in HIV-infected patients, clinicians should take into consideration all modifiable risk factors, in order to implement an effective prevention of this clinical issue.
Keywords: HIV infection, AIDS, atherosclerosis, cardiovascular risk, antiretroviral therapy, lipids, endothelium, human immunodeficiency virus (HIV), anti-HIVmedication, chronic inflammation, uncontrolled viral replication, efficacy of the combination antiretroviral treatment (cART), dyslipidemia, insulinresistance and endothelial damage
Current Pharmaceutical Biotechnology
Title: HIV and Accelerated Atheroprogression: Role of Antiretroviral Therapy
Volume: 13 Issue: 1
Author(s): Antonio Di Biagio, Valerio Del Bono, Raffaella Rosso and Claudio Viscoli
Affiliation:
Keywords: HIV infection, AIDS, atherosclerosis, cardiovascular risk, antiretroviral therapy, lipids, endothelium, human immunodeficiency virus (HIV), anti-HIVmedication, chronic inflammation, uncontrolled viral replication, efficacy of the combination antiretroviral treatment (cART), dyslipidemia, insulinresistance and endothelial damage
Abstract: The introduction of effective and potent treatments for human immunodeficiency virus (HIV) infection resulted in prolonged survival and better quality of life of HIV-infected patients. However, the longer survival and the anti-HIV medication side effects caused the emergence of new clinical issues, such as the increase in cardiovascular risk, favored by multiple factors, partly related to HIV infection itself, partly to the anti-HIV molecules. HIV infection itself may affect cardiovascular risk through chronic inflammation induced by uncontrolled viral replication, whereas long-term antiretroviral therapy may increase the cardiovascular risk through several mechanisms. Thus, due to the multiple and conflicting causes of cardiovascular disorders in HIV-infected patients, clinicians should take into consideration all modifiable risk factors, in order to implement an effective prevention of this clinical issue.
Export Options
About this article
Cite this article as:
Di Biagio Antonio, Del Bono Valerio, Rosso Raffaella and Viscoli Claudio, HIV and Accelerated Atheroprogression: Role of Antiretroviral Therapy, Current Pharmaceutical Biotechnology 2012; 13 (1) . https://dx.doi.org/10.2174/138920112798868520
DOI https://dx.doi.org/10.2174/138920112798868520 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Review of Macrolide Treatment of Atherosclerosis and Abdominal Aortic Aneurysms
Current Drug Targets - Infectious Disorders Discovery of a Novel Anti-Cancer Agent Targeting Both Topoisomerase I & II as Well as Telomerase Activities in Human Lung Adenocarcinoma A549 Cells In Vitro and In Vivo: Cinnamomum verum Component Cuminaldehyde
Current Cancer Drug Targets Muscular Gene Transfer Using Nonviral Vectors
Current Gene Therapy Editorial (Diabetes, Obesity and Vascular Disease - An Update)
Current Pharmaceutical Design Extraction Methods for Downstream Processing of Bioactive Compounds From Natural Sources
Current Biochemical Engineering (Discontinued) Novel Anti-Inflammatory Agents in COPD: Targeting Lung and Systemic Inflammation
Current Drug Targets Editorial (Hot Topics: Cardiovascular Dysfunction in Sepsis: From Basic Mechanisms to Clinical Management)
Current Vascular Pharmacology Metformin, A New Era for an Old Drug in the Treatment of Immune Mediated Disease?
Current Drug Targets Evaluation of Echocardiographic Abnormalities in HIV Positive Patients Treated with Antiretroviral Medications
Infectious Disorders - Drug Targets Multi-Targeted Natural Products Evaluation Based on Biological Activity Prediction with PASS
Current Pharmaceutical Design Carbon Nano Tubes: Novel Drug Delivery System in Amelioration of Alzheimer’s Disease
Combinatorial Chemistry & High Throughput Screening GPR40 Carboxylic Acid Receptor Family and Diabetes: A New Drug Target
Current Drug Targets Determinants of Left Ventricular Hypertrophy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Comparative Effectiveness of Pioglitazone and Rosiglitazone in Type 2 Diabetes, Prediabetes,and the Metabolic Syndrome: A Meta-Analysis
Current Diabetes Reviews Adipose Tissue: Something More than Just Adipocytes
Current Nutrition & Food Science Recent Advances in Sepsis Research: Novel Biomarkers and Therapeutic Targets
Current Medicinal Chemistry Erythropoietin Signaling and Neuroprotection
Current Signal Transduction Therapy The Kynurenine Pathway in the Acute and Chronic Phases of Cerebral Ischemia
Current Pharmaceutical Design Cyclophilin function in Cancer; lessons from virus replication
Current Molecular Pharmacology Epidemiology and Pathophysiology of Chronic Cough
Current Respiratory Medicine Reviews